Lipocine (NASDAQ:LPCN) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Lipocine (NASDAQ:LPCN) in a research note published on Monday morning. The brokerage issued a hold rating on the specialty pharmaceutical company’s stock.

Separately, Alliance Global Partners started coverage on Lipocine in a research report on Tuesday, September 24th. They set a “buy” rating and a $10.00 price objective for the company.

Lipocine Trading Down 0.6 %

NASDAQ LPCN opened at $4.99 on Monday. Lipocine has a 12 month low of $2.44 and a 12 month high of $11.79. The stock has a market cap of $26.69 million, a PE ratio of -6.57 and a beta of 1.24. The stock’s 50 day moving average is $5.17 and its 200 day moving average is $5.51.

Lipocine (NASDAQ:LPCN) last released its earnings results on Thursday, November 7th. The specialty pharmaceutical company reported ($0.44) EPS for the quarter. On average, analysts forecast that Lipocine will post -0.78 EPS for the current fiscal year.

Institutional Investors Weigh In On Lipocine

An institutional investor recently bought a new position in Lipocine stock. Dimensional Fund Advisors LP bought a new position in Lipocine Inc. (NASDAQ:LPCN) during the second quarter, according to its most recent 13F filing with the SEC. The fund bought 11,870 shares of the specialty pharmaceutical company’s stock, valued at approximately $98,000. Dimensional Fund Advisors LP owned about 0.22% of Lipocine as of its most recent SEC filing. Hedge funds and other institutional investors own 9.11% of the company’s stock.

About Lipocine

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.